Oncotarget

Research Papers:

Androgen receptor expression identifies patient with favorable outcome in operable triple negative breast cancer

Xiao-Qing Hu, Wei-Li Chen, Hai-Guang Ma and Ke Jiang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:56364-56374. https://doi.org/10.18632/oncotarget.16913

Metrics: PDF 898 views  |   HTML 1416 views  |   ?  


Abstract

Xiao-Qing Hu1, Wei-Li Chen2, Hai-Guang Ma1 and Ke Jiang2

1Department of Surgical Oncology, Wenzhou Central Hospital, Zhejiang, China

2Department of Breast Surgery, Yue Yang Hospital of Traditional Chinese & Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China

Correspondence to:

Ke Jiang, email: Surgeonjk@sina.com

Keywords: androgen receptor, triple negative breast cancer, prognostic biomarker, disease-free survival, overall survival

Received: December 27, 2016     Accepted: March 15, 2017     Published: April 07, 2017

ABSTRACT

In this study we sought to investigate the prevalence and prognostic value of androgen receptor (AR) status in operable triple-negative breast cancer (TNBC) patients. We collected the clinical data of 360 patients with TNBC, and found a positivity AR expression of 31.4% with a cut-off value of 10%. Tumors expressing the negative CK5/6 (P=0.013) and low Ki-67 (P=0.007) are more likely to have positive AR. In multivariate survival analysis, AR expression is correlated with increased DFS (HR=0.467, 95%CI 0.271-0.805; P=0.006) and OS (HR=0.488, 95%CI 0.267-0.894, P=0.020) independently. In addition, patients with AR+ tumors are more likely to have favorable outcome in patients with young, pre-menopausal, large tumor size, more node involvement (4+), high stage, high grade, vascular invasion+, P53+, CK5/6-, and higher Ki-67. Our study has indicated that the absence of AR might help to identify patients with relatively higher risk of disease relapse and death, and further clinical studies of anti-androgen agents are warranted to enrich the therapeutic strategy options for AR+ TNBCs.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16913